Cargando…
Metabolic and psychiatric effects of acyl coenzyme A binding protein (ACBP)/diazepam binding inhibitor (DBI)
Acyl coenzyme A binding protein (ACBP), also known as diazepam binding inhibitor (DBI) is a multifunctional protein with an intracellular action (as ACBP), as well as with an extracellular role (as DBI). The plasma levels of soluble ACBP/DBI are elevated in human obesity and reduced in anorexia nerv...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338362/ https://www.ncbi.nlm.nih.gov/pubmed/32632162 http://dx.doi.org/10.1038/s41419-020-2716-5 |
_version_ | 1783554657181761536 |
---|---|
author | Joseph, Adrien Moriceau, Stéphanie Sica, Valentina Anagnostopoulos, Gerasimos Pol, Jonathan Martins, Isabelle Lafarge, Antoine Maiuri, Maria Chiara Leboyer, Marion Loftus, Josephine Bellivier, Frank Belzeaux, Raoul Berna, Fabrice Etain, Bruno Capdevielle, Delphine Courtet, Philippe Dubertret, Caroline Dubreucq, Julien Thierry, D’. Amato Fond, Guillaume Gard, Sebastien Llorca, Pierre-Michel Mallet, Jasmina Misdrahi, David Olié, Emilie Passerieux, Christine Polosan, Mircea Roux, Paul Samalin, Ludovic Schürhoff, Franck Schwan, Raymond Magnan, Christophe Oury, Franck Bravo-San Pedro, José M. Kroemer, Guido |
author_facet | Joseph, Adrien Moriceau, Stéphanie Sica, Valentina Anagnostopoulos, Gerasimos Pol, Jonathan Martins, Isabelle Lafarge, Antoine Maiuri, Maria Chiara Leboyer, Marion Loftus, Josephine Bellivier, Frank Belzeaux, Raoul Berna, Fabrice Etain, Bruno Capdevielle, Delphine Courtet, Philippe Dubertret, Caroline Dubreucq, Julien Thierry, D’. Amato Fond, Guillaume Gard, Sebastien Llorca, Pierre-Michel Mallet, Jasmina Misdrahi, David Olié, Emilie Passerieux, Christine Polosan, Mircea Roux, Paul Samalin, Ludovic Schürhoff, Franck Schwan, Raymond Magnan, Christophe Oury, Franck Bravo-San Pedro, José M. Kroemer, Guido |
author_sort | Joseph, Adrien |
collection | PubMed |
description | Acyl coenzyme A binding protein (ACBP), also known as diazepam binding inhibitor (DBI) is a multifunctional protein with an intracellular action (as ACBP), as well as with an extracellular role (as DBI). The plasma levels of soluble ACBP/DBI are elevated in human obesity and reduced in anorexia nervosa. Accumulating evidence indicates that genetic or antibody-mediated neutralization of ACBP/DBI has anorexigenic effects, thus inhibiting food intake and inducing lipo-catabolic reactions in mice. A number of anorexiants have been withdrawn from clinical development because of their side effects including an increase in depression and suicide. For this reason, we investigated the psychiatric impact of ACBP/DBI in mouse models and patient cohorts. Intravenously (i.v.) injected ACBP/DBI protein conserved its orexigenic function when the protein was mutated to abolish acyl coenzyme A binding, but lost its appetite-stimulatory effect in mice bearing a mutation in the γ2 subunit of the γ-aminobutyric acid (GABA) A receptor (GABA(A)R). ACBP/DBI neutralization by intraperitoneal (i.p.) injection of a specific mAb blunted excessive food intake in starved and leptin-deficient mice, but not in ghrelin-treated animals. Neither i.v. nor i.p. injected anti-ACBP/DBI antibody affected the behavior of mice in the dark–light box and open-field test. In contrast, ACBP/DBI increased immobility in the forced swim test, while anti-ACBP/DBI antibody counteracted this sign of depression. In patients diagnosed with therapy-resistant bipolar disorder or schizophrenia, ACBP/DBI similarly correlated with body mass index (BMI), not with the psychiatric diagnosis. Patients with high levels of ACBP/DBI were at risk of dyslipidemia and this effect was independent from BMI, as indicated by multivariate analysis. In summary, it appears that ACBP/DBI neutralization has no negative impact on mood and that human depression is not associated with alterations in ACBP/DBI concentrations. |
format | Online Article Text |
id | pubmed-7338362 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-73383622020-07-09 Metabolic and psychiatric effects of acyl coenzyme A binding protein (ACBP)/diazepam binding inhibitor (DBI) Joseph, Adrien Moriceau, Stéphanie Sica, Valentina Anagnostopoulos, Gerasimos Pol, Jonathan Martins, Isabelle Lafarge, Antoine Maiuri, Maria Chiara Leboyer, Marion Loftus, Josephine Bellivier, Frank Belzeaux, Raoul Berna, Fabrice Etain, Bruno Capdevielle, Delphine Courtet, Philippe Dubertret, Caroline Dubreucq, Julien Thierry, D’. Amato Fond, Guillaume Gard, Sebastien Llorca, Pierre-Michel Mallet, Jasmina Misdrahi, David Olié, Emilie Passerieux, Christine Polosan, Mircea Roux, Paul Samalin, Ludovic Schürhoff, Franck Schwan, Raymond Magnan, Christophe Oury, Franck Bravo-San Pedro, José M. Kroemer, Guido Cell Death Dis Article Acyl coenzyme A binding protein (ACBP), also known as diazepam binding inhibitor (DBI) is a multifunctional protein with an intracellular action (as ACBP), as well as with an extracellular role (as DBI). The plasma levels of soluble ACBP/DBI are elevated in human obesity and reduced in anorexia nervosa. Accumulating evidence indicates that genetic or antibody-mediated neutralization of ACBP/DBI has anorexigenic effects, thus inhibiting food intake and inducing lipo-catabolic reactions in mice. A number of anorexiants have been withdrawn from clinical development because of their side effects including an increase in depression and suicide. For this reason, we investigated the psychiatric impact of ACBP/DBI in mouse models and patient cohorts. Intravenously (i.v.) injected ACBP/DBI protein conserved its orexigenic function when the protein was mutated to abolish acyl coenzyme A binding, but lost its appetite-stimulatory effect in mice bearing a mutation in the γ2 subunit of the γ-aminobutyric acid (GABA) A receptor (GABA(A)R). ACBP/DBI neutralization by intraperitoneal (i.p.) injection of a specific mAb blunted excessive food intake in starved and leptin-deficient mice, but not in ghrelin-treated animals. Neither i.v. nor i.p. injected anti-ACBP/DBI antibody affected the behavior of mice in the dark–light box and open-field test. In contrast, ACBP/DBI increased immobility in the forced swim test, while anti-ACBP/DBI antibody counteracted this sign of depression. In patients diagnosed with therapy-resistant bipolar disorder or schizophrenia, ACBP/DBI similarly correlated with body mass index (BMI), not with the psychiatric diagnosis. Patients with high levels of ACBP/DBI were at risk of dyslipidemia and this effect was independent from BMI, as indicated by multivariate analysis. In summary, it appears that ACBP/DBI neutralization has no negative impact on mood and that human depression is not associated with alterations in ACBP/DBI concentrations. Nature Publishing Group UK 2020-07-06 /pmc/articles/PMC7338362/ /pubmed/32632162 http://dx.doi.org/10.1038/s41419-020-2716-5 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Joseph, Adrien Moriceau, Stéphanie Sica, Valentina Anagnostopoulos, Gerasimos Pol, Jonathan Martins, Isabelle Lafarge, Antoine Maiuri, Maria Chiara Leboyer, Marion Loftus, Josephine Bellivier, Frank Belzeaux, Raoul Berna, Fabrice Etain, Bruno Capdevielle, Delphine Courtet, Philippe Dubertret, Caroline Dubreucq, Julien Thierry, D’. Amato Fond, Guillaume Gard, Sebastien Llorca, Pierre-Michel Mallet, Jasmina Misdrahi, David Olié, Emilie Passerieux, Christine Polosan, Mircea Roux, Paul Samalin, Ludovic Schürhoff, Franck Schwan, Raymond Magnan, Christophe Oury, Franck Bravo-San Pedro, José M. Kroemer, Guido Metabolic and psychiatric effects of acyl coenzyme A binding protein (ACBP)/diazepam binding inhibitor (DBI) |
title | Metabolic and psychiatric effects of acyl coenzyme A binding protein (ACBP)/diazepam binding inhibitor (DBI) |
title_full | Metabolic and psychiatric effects of acyl coenzyme A binding protein (ACBP)/diazepam binding inhibitor (DBI) |
title_fullStr | Metabolic and psychiatric effects of acyl coenzyme A binding protein (ACBP)/diazepam binding inhibitor (DBI) |
title_full_unstemmed | Metabolic and psychiatric effects of acyl coenzyme A binding protein (ACBP)/diazepam binding inhibitor (DBI) |
title_short | Metabolic and psychiatric effects of acyl coenzyme A binding protein (ACBP)/diazepam binding inhibitor (DBI) |
title_sort | metabolic and psychiatric effects of acyl coenzyme a binding protein (acbp)/diazepam binding inhibitor (dbi) |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338362/ https://www.ncbi.nlm.nih.gov/pubmed/32632162 http://dx.doi.org/10.1038/s41419-020-2716-5 |
work_keys_str_mv | AT josephadrien metabolicandpsychiatriceffectsofacylcoenzymeabindingproteinacbpdiazepambindinginhibitordbi AT moriceaustephanie metabolicandpsychiatriceffectsofacylcoenzymeabindingproteinacbpdiazepambindinginhibitordbi AT sicavalentina metabolicandpsychiatriceffectsofacylcoenzymeabindingproteinacbpdiazepambindinginhibitordbi AT anagnostopoulosgerasimos metabolicandpsychiatriceffectsofacylcoenzymeabindingproteinacbpdiazepambindinginhibitordbi AT poljonathan metabolicandpsychiatriceffectsofacylcoenzymeabindingproteinacbpdiazepambindinginhibitordbi AT martinsisabelle metabolicandpsychiatriceffectsofacylcoenzymeabindingproteinacbpdiazepambindinginhibitordbi AT lafargeantoine metabolicandpsychiatriceffectsofacylcoenzymeabindingproteinacbpdiazepambindinginhibitordbi AT maiurimariachiara metabolicandpsychiatriceffectsofacylcoenzymeabindingproteinacbpdiazepambindinginhibitordbi AT leboyermarion metabolicandpsychiatriceffectsofacylcoenzymeabindingproteinacbpdiazepambindinginhibitordbi AT loftusjosephine metabolicandpsychiatriceffectsofacylcoenzymeabindingproteinacbpdiazepambindinginhibitordbi AT bellivierfrank metabolicandpsychiatriceffectsofacylcoenzymeabindingproteinacbpdiazepambindinginhibitordbi AT belzeauxraoul metabolicandpsychiatriceffectsofacylcoenzymeabindingproteinacbpdiazepambindinginhibitordbi AT bernafabrice metabolicandpsychiatriceffectsofacylcoenzymeabindingproteinacbpdiazepambindinginhibitordbi AT etainbruno metabolicandpsychiatriceffectsofacylcoenzymeabindingproteinacbpdiazepambindinginhibitordbi AT capdevielledelphine metabolicandpsychiatriceffectsofacylcoenzymeabindingproteinacbpdiazepambindinginhibitordbi AT courtetphilippe metabolicandpsychiatriceffectsofacylcoenzymeabindingproteinacbpdiazepambindinginhibitordbi AT dubertretcaroline metabolicandpsychiatriceffectsofacylcoenzymeabindingproteinacbpdiazepambindinginhibitordbi AT dubreucqjulien metabolicandpsychiatriceffectsofacylcoenzymeabindingproteinacbpdiazepambindinginhibitordbi AT thierrydamato metabolicandpsychiatriceffectsofacylcoenzymeabindingproteinacbpdiazepambindinginhibitordbi AT fondguillaume metabolicandpsychiatriceffectsofacylcoenzymeabindingproteinacbpdiazepambindinginhibitordbi AT gardsebastien metabolicandpsychiatriceffectsofacylcoenzymeabindingproteinacbpdiazepambindinginhibitordbi AT llorcapierremichel metabolicandpsychiatriceffectsofacylcoenzymeabindingproteinacbpdiazepambindinginhibitordbi AT malletjasmina metabolicandpsychiatriceffectsofacylcoenzymeabindingproteinacbpdiazepambindinginhibitordbi AT misdrahidavid metabolicandpsychiatriceffectsofacylcoenzymeabindingproteinacbpdiazepambindinginhibitordbi AT olieemilie metabolicandpsychiatriceffectsofacylcoenzymeabindingproteinacbpdiazepambindinginhibitordbi AT passerieuxchristine metabolicandpsychiatriceffectsofacylcoenzymeabindingproteinacbpdiazepambindinginhibitordbi AT polosanmircea metabolicandpsychiatriceffectsofacylcoenzymeabindingproteinacbpdiazepambindinginhibitordbi AT rouxpaul metabolicandpsychiatriceffectsofacylcoenzymeabindingproteinacbpdiazepambindinginhibitordbi AT samalinludovic metabolicandpsychiatriceffectsofacylcoenzymeabindingproteinacbpdiazepambindinginhibitordbi AT schurhofffranck metabolicandpsychiatriceffectsofacylcoenzymeabindingproteinacbpdiazepambindinginhibitordbi AT schwanraymond metabolicandpsychiatriceffectsofacylcoenzymeabindingproteinacbpdiazepambindinginhibitordbi AT metabolicandpsychiatriceffectsofacylcoenzymeabindingproteinacbpdiazepambindinginhibitordbi AT magnanchristophe metabolicandpsychiatriceffectsofacylcoenzymeabindingproteinacbpdiazepambindinginhibitordbi AT ouryfranck metabolicandpsychiatriceffectsofacylcoenzymeabindingproteinacbpdiazepambindinginhibitordbi AT bravosanpedrojosem metabolicandpsychiatriceffectsofacylcoenzymeabindingproteinacbpdiazepambindinginhibitordbi AT kroemerguido metabolicandpsychiatriceffectsofacylcoenzymeabindingproteinacbpdiazepambindinginhibitordbi |